Details for Patent: 8,188,085

« Back to Dashboard

Which drugs does patent 8,188,085 protect, and when does it expire?

Patent 8,188,085 protects BREXAFEMME and is included in one NDA.

This patent has nine patent family members in seven countries.

Summary for Patent: 8,188,085

Title:	Antifungal agents
Abstract:	Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
Inventor(s):	Mark L. Greenlee, Robert Wilkening, James Apgar, Donald Sperbeck, Kenneth J. Wildonger, DongFang Meng, Dann L. Parker, JR., Gregory J. Pacofsky, Brian H. Heasley, Ahmed Mamai, Kingsley Nelson
Assignee:	Seynexis Inc , Scynexis Inc
Application Number:	US12/461,318
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,188,085

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes			Y	Y		TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)

International Family Members for US Patent 8,188,085

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009282474
Canada	2731941
China	102176827
China	104877001
European Patent Office	2326181
Hong Kong	1214271